Skip to content

Author

Andrew Tsourkas

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Jul 2026

Resolving Heterogeneity of Targeted Lipid Nanoparticles Through Solution‐Based Biophysical Analyses

Targeted lipid nanoparticles (tLNPs) enable cell‐specific nucleic acid delivery through covalent attachment of targeting ligands that drive receptor‐mediated LNP uptake. tLNPs are potentially promising for pregnancy‑associated applications where precise delivery is required to minimize maternal toxicity and protect fetal health. Yet, rational tLNP design is limited by an incomplete understanding of how physicochemical properties influence biological performance. Traditional analytical methods report only ensemble‐averaged properties, leaving the nanoscale heterogeneity of tLNPs unresolved. Here, we utilize asymmetric flow field‐flow fractionation integrated with in‐line UV spectral analysis, light scattering, and synchrotron small‐angle X‐ray scattering (AF4‐UV‐DLS‐MALS‐SAXS) to resolve ligand‐dependent tLNP subpopulations that differ in size, shape, composition, and relative abundance. Protein conjugation preserves the internal lipid–RNA nanostructure of base LNPs but substantially increases particle heterogeneity, particularly for larger and multivalent ligands. Despite increased heterogeneity, tLNPs functionalized with higher‐avidity ligands achieve more effective targeted placental RNA delivery in mice. Chemometric SAXS analyses reveal that only SAXS‐resolved tLNP subpopulations, not ensemble‐averaged parameters, correlate with targeted placental transfection in vivo, whereas bulk physicochemical metrics more strongly associate with nonspecific hepatic delivery. Together, this work harnesses a separation‐coupled biophysical platform to resolve previously inaccessible tLNP subpopulations and provides insights to inform rational engineering of next‐generation targeted RNA therapeutics.

Hannah C. Geisler, Hannah C. Safford, Ajay S. Thatte et al. · 0 citations
Open access Jul 2026

DSPE-PEG does not retain targeting antibodies on LNP surfaces in vivo; a higher molecular weight anchor is required

Extrahepatic delivery of lipid nanoparticles (LNPs) to non-phagocytic cells is a major challenge, with the leading strategy involving surface functionalization with target-specific monoclonal antibody (mAb) ligands. We investigate the stability of mAb-conjugated LNPs using two anchoring systems: the commonly used DSPE-PEG2kDa-maleimide and a block copolymer, PCL5kDa-b-PEG2kDa -maleimide, with the hypothesis that conjugation to a 150,000 Da antibody could overwhelm the relatively small ∼600 Da aliphatic anchor on the PEG-lipid in vivo. Shedding of the mAB would compromise targeting. Conjugation integrity following IV injection was assessed by tagging LNPs and mAbs with metal ion tracers that could be quantified by ICP-MS. Results show that DSPE-PEG-mAb rapidly (within 1h) dissociates from LNPs in blood, leading to accelerated LNP clearance. In contrast, mAbs conjugated using PCL-b-PEG remained stably associated with the LNP over the 24h circulation and clearance of the construct. Results are connected to a thermodynamic model that reproduces experimental findings for PEG-anchor(-mAb) shedding in vitro and in vivo. This study identifies anchoring strength as a critical, unconsidered parameter for in vivo performance when conjugating mAbs to LNPs for extrahepatic delivery. Graphical abstract

Brian K. Wilson, Lucas D. Johnson, Jason Liu et al. · 0 citations